Aidoc Secures $150M in Funding to Expand Clinical AI Solutions

Healthcare AI company Aidoc has raised $150 million in new financing, aiming to expand its clinical AI solutions into oncology and cardiovascular disease. The funding round, led by General Catalyst and Square Peg, with participation from NVentures (NVIDIA's venture capital arm) and four major U.S. health systems, brings Aidoc's total funding to $370 million.

Expansion of CARE Foundation Model

Aidoc's CARE (Clinical AI Reasoning Engine) foundation model, which assists physicians in clinical decisions, is at the forefront of the company's growth strategy. Two CARE-powered solutions have already earned FDA clearance, including the Rib Fractures triage solution cleared in February 2025.

The company plans to transition all its models to CARE, with expectations to cover 90% of clinically relevant diseases, including cancer and cardiovascular conditions, within three years. Elad Walach, CEO of Aidoc, stated, "CARE compresses decades of roadmap into years—bringing forward a future where AI supports every patient encounter, helping physicians provide the care they believe their patients deserve."

Enterprise-Grade AI Platform and Partnerships

Aidoc is doubling down on its enterprise-grade AI platform, aiOS, designed to enable health systems to deploy and govern multiple AI solutions responsibly. The platform hosts both Aidoc and external solutions, with 69% of customers currently running non-Aidoc models on aiOS.

Strategic collaborations with Amazon Web Services and NVIDIA are enhancing the aiOS platform and developing guidelines for AI implementation. Through these initiatives, Aidoc plans to invest over $150 million to bring CARE to market, combining high-performance compute and AI development platforms.

Impact on Healthcare Systems

Aidoc currently supports care for more than 45 million patients annually across over 150 health systems, with plans to grow to 100 million in three years. The company's AI-powered tools have shown significant impact in clinical settings. Dr. Roxanna Gapstur, President and CEO of WellSpan Health, reported that Aidoc has helped their radiologists analyze more than 200,000 cases in one year, leading to a significant reduction in critical diagnosis delays.

As Aidoc continues to expand its reach and capabilities, the company aims to reduce diagnostic errors, improve patient outcomes, and alleviate cognitive overload for healthcare professionals. With its latest funding and technological advancements, Aidoc is poised to play a pivotal role in shaping the future of AI-assisted healthcare.